Ignite Creation Date:
2025-12-25 @ 2:02 AM
Ignite Modification Date:
2026-02-25 @ 7:05 PM
Study NCT ID:
NCT00544960
Status:
COMPLETED
Last Update Posted:
2010-08-27
First Post:
2007-10-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Randomized Phase 2 Study of AT-101 in Combination With Docetaxel in Relapsed/Refractory Non-Small Cell Lung Cancer
Sponsor:
Ascenta Therapeutics
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
AT-101-CS-204
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Brian Wood, Associate Director, Clinical Development
Old Organization:
Ascenta Therapeutics